email this
print this
SAVE AND SHARE
 |
|
|
|
|
|
|
 |
Rohm & Haas, a century in Philadelphia
Go to the Rohm & Haas Web site, which includes a history of the company.
Go to the Dow Chemical Co.Web site.
While Rohm & Haas has spent years making itself a force in the specialty-chemicals market, it also has been accused of causing some of its workers to fall ill.
Below are links to some of The Inquirer's archived coverage:
Cancer lawsuit filed against Rohm & Haas
Aug 6, 2005: The plaintiffs: A scientist's widow and a man battling the disease. Both men worked at the firm's Montco facility. Read the article.
A Pa. medical mystery and a legal quandary
March 6, 2007: A debate on brain tumors, need for screenings. Read the article
Suit names Rohm, Haas in death from cancer
May 18, 2007: Olivia Ranalli was the 10th leather-unit worker to die of brain cancer. The firm says an earlier study found no link. Read the article
Rohm changes course on cancer study
Jan. 22, 2008: Rohm & Haas Co. said today it plans to hire an external academic team to take over its investigation into a series of brain cancers at its main research center, following a harsh federal critique of the company's research. Read the article
Go to the Dow Chemical Co.Web site.
While Rohm & Haas has spent years making itself a force in the specialty-chemicals market, it also has been accused of causing some of its workers to fall ill.
Below are links to some of The Inquirer's archived coverage:
Cancer lawsuit filed against Rohm & Haas
Aug 6, 2005: The plaintiffs: A scientist's widow and a man battling the disease. Both men worked at the firm's Montco facility. Read the article.
A Pa. medical mystery and a legal quandary
March 6, 2007: A debate on brain tumors, need for screenings. Read the article
Suit names Rohm, Haas in death from cancer
May 18, 2007: Olivia Ranalli was the 10th leather-unit worker to die of brain cancer. The firm says an earlier study found no link. Read the article
Rohm changes course on cancer study
Jan. 22, 2008: Rohm & Haas Co. said today it plans to hire an external academic team to take over its investigation into a series of brain cancers at its main research center, following a harsh federal critique of the company's research. Read the article
